Alzamend Neuro™ Announces TV Icon Willie Aames as International Spokesperson 80’s &; 90’s Star Tapped as Creative Advisor to Drive $50 MM Reg. A+ “Mini IPO”
Salt Lake City, UT – (Globe Newswire – January 9, 2017) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today Willie Aames will serve as its International Spokesperson while joining the team as Creative Advisor. The Company stated that with its recent launch of its Regulation A+ Tier II Offering online at www.AlzamendRegA.com™, it looks forward to the many contributions, inspiration and leadership that Aames will provide. With the Company’s campaign targeted to raise $50MM in new equity capital in less than a full year and able to take investment immediately,
the addition of Aames is strategic and notable. On December 8, 2016, the Company was notified by the SEC that it had qualified its Form 1-A Application allowing the Company to move forward with the Offering which will leverage the key component of the Reg. A+ Tier II rules which allow for the solicitation of the general public as well as traditional investors
and financial institutions.
Although Willie Aames has starred in over 22 network series, Aames is best known worldwide for playing the iconic “Tommy Bradford” on the 1970s television series Eight Is Enough and Scott Baio’s heartwarming wingman “Buddy Lembeck”t; on the 1980s television hit series “Charles in Charge.” Aames also went on to star in 6 feature films. During the 1990’s and through 2008 Aames developed his marketing skills making a name for himself as an award winning, platinum selling writer, producer and director. During this time, Aames successfully developed strategies, scripts and marketing plans for a myriad of companies including Fortune 500 titans Sprint, Northwest Airlines, Marion Labs and
Helzberg Diamonds, a Berkshire Hathaway company. Aames also served as executive vice president of Pamplin Communications where he successfully developed several children shows that became “sell through product” for Sony Wonder, Walmart and Toys R Us distribution channels.
During the mid-2000’s, Aames endured a series of personal setbacks including a personal bankruptcy that left him homeless but became known and revered for his perseverance and resilience. Determined to overcome and learn from his experiences, Aames again made headlines when he became a licensed financial advisor appearing on NBC’s “Today”
show. “What I experienced I wouldn’t wish on anyone” the actor stated, “But once I survived it, I was determined to make a difference in the lives of others.” In talking of the extreme circumstances, he explained: “Those years changed my entire perspective about everything, my world perspective, and my life, its meaning and what my contributions should be.” His
success and triumph was celebrated and documented on Oprah Winfrey’s popular hit, “Where are they Now.”
Aames’ family has a long history with Alzheimer’s. His paternal grandfather was Dr. Albert Upton, PhD, an acclaimed professor, author and the Dean of the English department and the Head of Russian Literature for Whittier College in Southern California. Dr. Upton pioneered the concept that the IQ of a college freshman could be raised by teaching a course in semantics. The course and the accompanying book were titled “Design for Thinking” which is still in use at Whittier College. Aames spent his early adulthood watching this brilliant educator, who literally “wrote the book on thinking”, slowly succumb to Alzheimer’s.
Aames’ grandmother Alleen, who was brilliant in her own right as a biochemist, also passed away due to Alzheimer’s. Armed with his personal experiences in losing two significant family members to AD, Aames has noted his personal quest to effect change and progress while making a difference in others’ lives. Aames expressed an unyielding commitment to
use all of his talents for the development and success of Alzamend Neuro™ and to raise awareness of AD. “I believe that any step forward in the fight against Alzheimer’s is a good step, and I can think of no endeavor more worthy to undertake than to help take positive steps towards ending what has been called ‘the most feared disease’.”
The Company recommends any investors to read its Form 1-A Offering Statement and other public reports and financial statements that may be filed with the Securities and Exchange Commission for further information. All public filings, financial statements, management profiles and other Company information are available on the Company’s web site. The
Company’s web domain is www.Alzamend.com™ and its Regulation A+ Tier II Offering web domain is www.AlzamendRegA.com™.
About Alzamend Neuro™, Inc.
Alzamend Neuro™, Inc. is a Delaware corporation doing business in the State of Utah. The mission of Alzamend Neuro™ is to support the full product development life cycle of treatment and cures for Alzheimer’s driven by the belief that strong support of research is the foundation for true innovation. The Company is providing current hope though the
commercialization of existing patented intellectual property and know-how while simultaneously funding future hope through advance research and development.
As its first step in its vision, Alzamend Neuro™, has licensed a patented mutant peptide for use in immunotherapy from the University of South Florida. It is one of the Company’s strategic goals to support the continuing research by the team at the USF Health Byrd Alzheimer’s Institute and to develop and commercialize their results into meaningful solutions.
From his family’s personal experience with 6 relatives having been afflicted with AD, Mr. Milton “Todd” Ault, III, the Company’s Founder and Chairman, diligently studied the status of treatments and the landscape of medical technology. Mr. Ault selected the Byrd Institute and its formative intellectual property and formed the Company. With over twenty-five
years of experience on Wall Street buying and selling companies as an activist driven by his relentless passion for business and technology, Mr. Ault’s efforts have culminated in a commitment to depart from the traditional while forging ahead with an innovative yet disruptive path to financing the commercialization and the discovery of future solutions.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and those statements are subject to the safe harbor created by
those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company cautions that these forward-looking statements are further qualified by other factors. The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.